GlassScriptPhysician profile
Mailenys Ortega
NPI 1154996056
$9,264.55
in general payments reported to CMS, 2019-2025
15 companies · $38.17 in 2025
The $38.17 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $369 · 2022: $4,334 · 2023: $3,288 · 2024: $1,235 · 2025: $38.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $2,061 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $2,061.34 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,368.95 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $2,022.09 | 2022 | |
| Celgene Corporation | $1,463.46 | 2022 | |
| Abbvie INC. | $1,004.49 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $345.40 | 2021-2024 | Entyvio |
| Janssen Scientific Affairs, LLC | $281.07 | 2022-2024 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $262.55 | 2021-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.64 | 2022-2024 | Xifaxan |
| Gilead Sciences, INC. | $143.86 | 2024 | |
| Genzyme Corporation | $42.86 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $28.30 | 2024 | Iqirvo |
| Sandoz INC. | $25.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.56 | 2025 | |
| Lilly USA, LLC | $17.91 | 2023 | |
| Redhill Biopharma INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mailenys Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.